Coeptis Therapeutics (NASDAQ:ZSQR) Releases Earnings Results

Coeptis Therapeutics (NASDAQ:ZSQR) issued its earnings results on Thursday. The company reported ($0.65) EPS for the quarter, FiscalAI reports. Coeptis Therapeutics had a negative return on equity of 110.89% and a negative net margin of 803.96%.The company had revenue of $0.11 million during the quarter.

Coeptis Therapeutics Price Performance

Shares of Coeptis Therapeutics stock traded down $0.59 on Friday, hitting $9.25. The company’s stock had a trading volume of 173,002 shares, compared to its average volume of 73,109. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.16 and a current ratio of 4.16. Coeptis Therapeutics has a 1 year low of $6.80 and a 1 year high of $21.41. The firm has a fifty day moving average price of $12.66 and a 200-day moving average price of $13.72. The company has a market capitalization of $57.54 million, a price-to-earnings ratio of -3.10 and a beta of -0.09.

Institutional Investors Weigh In On Coeptis Therapeutics

Several institutional investors have recently bought and sold shares of ZSQR. Marshall Wace LLP acquired a new stake in Coeptis Therapeutics in the 4th quarter worth about $259,000. Yorkville Advisors Global LP acquired a new stake in Coeptis Therapeutics in the 3rd quarter worth about $140,000. State Street Corp boosted its holdings in Coeptis Therapeutics by 35.0% in the 4th quarter. State Street Corp now owns 26,830 shares of the company’s stock worth $382,000 after buying an additional 6,962 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Coeptis Therapeutics by 12.6% in the 4th quarter. Geode Capital Management LLC now owns 42,097 shares of the company’s stock worth $600,000 after buying an additional 4,721 shares during the last quarter. Finally, Steward Partners Investment Advisory LLC boosted its holdings in Coeptis Therapeutics by 100.0% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 5,000 shares of the company’s stock worth $71,000 after buying an additional 2,500 shares during the last quarter. 13.88% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Coeptis Therapeutics in a research note on Wednesday, January 21st. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Coeptis Therapeutics currently has a consensus rating of “Sell”.

Coeptis Therapeutics Company Profile

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.